Immunology Department Metrics

View the clinical trials, grants and publications from the Department of Immunology.

Clinical Trials
CLINICAL TRIAL 18786
A Phase 2, Randomized, Multi-institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Yervoy (Ipilimumab)

CLINICAL TRIAL 19662
Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer
Condition: Gynecological Tumor
Intervention: Atezolizumab (Tecentriq)

CLINICAL TRIAL 19724
Managed Access Program (MAP) To Provide Access To CTL019, For Acute Lymphoblastic Leukemia (ALL) Or Diffuse Large B-Cell Lymphoma (DLBCL) Patients With Out Of Specification Leukapheresis Product And/Or Manufactured Tisagenlecleucel Out Of Specification For Commercial Release
Condition: Malignant Hematology
Intervention:

CLINICAL TRIAL 19837
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients with Soft Tissue Sarcoma
Condition: Sarcoma
Intervention: IL-2 (Interleukin-2); MESNA (); TIL (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 19936
Maintenance Systemic Therapy versus Local Consolidative Therapy (Lct) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (Nsclc): A Randomized Phase II/III Trial
Condition: Genitourinary
Intervention: Alimta (Pemetrexed); Gemzar (gemcitabine); Pembrolizumab (Keytruda); Pemetrexed (); Taxotere (docetaxel); docetaxel (); gemcitabine ()

CLINICAL TRIAL 19877
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-Cell Lymphomas
Condition: Malignant Hematology
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Varlilumab ()

CLINICAL TRIAL 19960
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic Car T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Patients with Relapsed/Refractory Large B-Cell and Follicular Lymphoma
Condition: Malignant Hematology
Intervention: ALLO-501 (); ALLO-647 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20042
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients with MDS and Secondary AML
Condition: Malignant Hematology
Intervention: Cladribine (); Cytarabine (Cytosine Arabinoside); Daunomycin (daunorubicin); G-CSF (); Idarubicin (); Zevados (Idarubicin); daunorubicin ()

CLINICAL TRIAL 20131
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Condition: Malignant Hematology
Intervention: Alkeran (Melphalan); Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); G-CSF (); Melphalan (); Mycophenolate Mofetil (); Rapamune (Sirolimus); Rapamycin (Sirolimus); Sirolimus (); Tacrolimus (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20253
Open Label, Multi-Center, Phase 1b Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR-BCMA T cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: CT053 ()

CLINICAL TRIAL 20348
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase II/III randomized study of chemoradiation versus chemoradiation plus Atezolizumab
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); Paraplatin (carboplatin); Radiotherapy (); carboplatin (); cisplatin (); etoposide ()

CLINICAL TRIAL 20313
Neoadjuvant Immunotherapy with Intratumoral Tavokinogene Telseplasmid (Tavo) plus Electroporation in Combination with Intravenous Nivolumab in Patients with Operable Locally- Regionally Advanced Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Nivolumab (Opdivo); Tavo-EP ()

CLINICAL TRIAL 20329
The PISCES study: A Multicenter Phase 2, Open-Label Study of Intratumoral Tavokinogene Telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Intravenous Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment
Condition: Cutaneous
Intervention: Pembrolizumab (Keytruda); Tavo-EP ()

CLINICAL TRIAL 20397
A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Condition: Immunotherapy
Intervention: Itacitinib ()

CLINICAL TRIAL 20487
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Condition: Breast
Intervention: Herceptin (Trastuzumab); Pertuzumab (); Radiotherapy (); Trastuzumab (); rhuMAb HER2 (Trastuzumab)

CLINICAL TRIAL 20494
A Phase II Study of High Dose Bolus IL2 in Combination with Low Dose Ipilimumab Followed Sequentially by Nivolumab in Patients with Inoperable Stage III or Stage IV Melanoma Who Have Failed Prior Anti-PD1 Immunotherapy
Condition: Cutaneous
Intervention: Aldesleukin (Interleukin-2); BMS-936558 (Nivolumab); IL-2 (Interleukin-2); Interleukin-2 (); Ipilimumab (); Nivolumab (Opdivo); Proleukin (Interleukin-2); Yervoy (Ipilimumab)

CLINICAL TRIAL 20578
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmocodynamics of ALLO-501A, an Anti-CD19 Allogeneic Car T Cell Therapy in Subjects with Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Condition: Malignant Hematology
Intervention: ALLO-501A (); ALLO-647 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 20557
A Phase II, Open-Label, Multicenter, Randomized Study of Efficacy and Safety of RO7198457 in Combination with Pembrolizumab versus Pembrolizumab in Patients with Previously Untreated Advanced Melanoma
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 20575
A Phase 1 Study of CG0070 Combined with Nivolumab in Cisplatin Ineligible Patients with Muscle Invasive Bladder Cancer (MIBC)
Condition: Genitourinary
Intervention: BMS-936558 (Nivolumab); CG0070 (); DDM (); Nivolumab (Opdivo)

CLINICAL TRIAL 20571
Optimizing Cellular and Humoral Immunity to Pneumococcus by Vaccination with Pneumococcal 13-valent conjugate vaccine before and after CD19-targeted CAR T-cell Immunotherapy
Condition: Immunotherapy
Intervention: CD19 CAR T Cells (); PCV13 ()

CLINICAL TRIAL 20711
A Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)
Condition: Genitourinary
Intervention: CG0070 (); DDM (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 20720
S1827, MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Condition: Thoracic
Intervention:

CLINICAL TRIAL 20722
Phase III Randomized Trial of Pleurectomy/Decortication plus Chemotherapy with or without Adjuvant Hemithoracic Intenstiy-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)
Condition: Thoracic
Intervention:

CLINICAL TRIAL 20839
A Phase 3, Randomized, Open-label Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); NKTR-214 (Bempegaldesleukin); Nivolumab (Opdivo)

CLINICAL TRIAL 20794
Neoadjuvant Cemiplimab in Stage I-II Merkel Cell Carcinoma: Safety and Biomarker Analysis
Condition: Cutaneous
Intervention: Cemiplimab (); REGN2810 (Cemiplimab)

CLINICAL TRIAL 20899
Phase I/II Study of Stereotactic Radiation and Abemaciclib in the Management of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases
Condition: Breast
Intervention: Abemaciclib (); Endocrine Therapy (); LY2835219 (Abemaciclib); Radiotherapy ()

CLINICAL TRIAL 21214
Association of Gender with Adverse Events, Prescribing Patterns and Oncologic outcomes in Patients being treated with Immuno-Oncology Agents
Condition: Cutaneous
Intervention:

CLINICAL TRIAL 21239
Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Condition: Cutaneous
Intervention: BMS-936558 (Nivolumab); Ipilimumab (); Nivolumab (Opdivo); Sargramostim (); Yervoy (Ipilimumab)

CLINICAL TRIAL 21375
A Multicenter Validation of Genomic Subtyping and Whole Transcriptome Profiling for Predicting Non-Organ Confined Disease in Patients with Clinical T1/T2 Urothelial Carcinoma of the Bladder
Condition: Genitourinary
Intervention:

CLINICAL TRIAL 50399
Mechanisms of Functional Heterogeneity of Tumor Associated Macrophages in Glioblastoma
Condition: Neurologic Oncology
Intervention:

Grants
  • 2/2 Ponce School of Medicine-Moffitt Cancer Center Partnership
    Sponsor: Nat Institutes of Health
    PI (Contact):Wright, K.,PI (MPI):Monteiro, A.
  • The Mechanism of PV-10 in Regression of Solid Tumors
    Sponsor: Provectus Pharmaceuticals, Inc.
    PI:Pilon-Thomas, S.
  • Production Assistance for Cellular Therapies (PACT) - Cell Processing Facilities
    Sponsor: Nat Institutes of Health
    PI:Kelley, L.
  • Augmenting T Cell Trafficking and Functionality through Novel Combinations of Epigenetic Agents and PD-1 Blockade
    Sponsor: Nat Institutes of Health
    PI:Beg, A.
  • Development of CAR-T/CER-T Therapies for Ovarian Cancer
    Sponsor: Certainty Therapeutics, Inc.
    PI:Conejo-Garcia, J.
  • Regulatory Dendritic Cells in Cancer
    Sponsor: Nat Institutes of Health
    PI:Conejo-Garcia, J.
  • Defining Impact of HDAC Inhibitors on Tumor Immunogenicity, T Cell Functionality and PD-1 Blockade Response in NSCLC Patients
    Sponsor: US Army
    PI:Beg, A.
  • Regulation of dendritic cell function and tumor immunity by TIM-3
    Sponsor: Nat Institutes of Health
    PI:Ruffell, B.
  • B Cell-dependent Anti-tumor Immunity in Ovarian Cancer
    Sponsor: Nat Institutes of Health
    PI:Conejo-Garcia, J.
  • Functional reprogramming of tumor-MDSC through antibody-based therapies Targeting Notch Ligands
    Sponsor: Nat Institutes of Health
    PI:Rodriguez, P.
  • Imaging Acidosis and Immune Therapy in PDAC
    Sponsor: Nat Institutes of Health
    PI (Contact):Pilon-Thomas, S.,PI (MPI):Gillies, R.
  • Targetable Epidgenetic Mechanism Driving Cutaneous T Cell Lymphoma
    Sponsor: Nat Institutes of Health
    PI (Contact):Conejo-Garcia, J.,PI (MPI):Pinilla, J.,PI (MPI):Sokol, L.
  • Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment.
    Sponsor: Nat Institutes of Health
    PI:Abate Daga, D.
  • Engineering and efficacy of biologics against HPV oncoproteins
    Sponsor: Nat Institutes of Health
    PI (Contact):Pilon-Thomas, S.,PI (MPI):Enderling, H.
  • HDAC6 inhibition and Treg-targeting as immunotherapeutic strategy for Non-small cell lung cancer
    Sponsor: Amer Lung Assoc
    PI:Adeegbe, D.
  • Breast cancer immunotherapy with anti-TIM-3
    Sponsor: US Army
    PI:Ruffell, B.
  • Exploiting the Immune Mapping of the Tumor Microenvironment to Improve Immunotherapy of Melanoma
    Sponsor: Adelson (Miriam & Sheldon) Medical Res Fdtn
    PI:Mulé, J.
  • Determine the effects of the TP-0184 and its derivatives (second generation) on myeloid-derived suppressor cell (MDSC)-mediated suppressive functions and improve the local bone marrow (BM) microenvironment in patients with MDS
    Sponsor: Tolero Pharmaceuticals
    PI (Contact):Wright, K.,PI:Eksioglu, E.
  • Intellia Research Collaboration - Project 1: Advancing Neoantigen-Specific T Cells
    Sponsor: Intellia Therapeutics
    PI:Pilon-Thomas, S.,CO-PI:Abate Daga, D.
  • A Phase II Biomarker Trial of CC-122 in Combination with Nivolumab in Advanced Melanoma
    Sponsor: Celgene Corp.
    PI:Pilon-Thomas, S.
  • Notch signaling boosts T cell-based immunotherapy
    Sponsor: Florida Biomedical Research Program (FBRP)
    PI:Rodriguez, P.,CO-PI:Luca, V.
  • Immune Modulation by TIM-3
    Sponsor: Tesaro, Inc.
    PI:Ruffell, B.
  • Myst/Turnstone– Moffitt Collaboration - Melanoma & Colorectal
    Sponsor: Turnstone Biologics
    PI (Contact):Pilon-Thomas, S.,CO-PI:Beatty, M.,CO-PI:Fleming, J.,CO-PI:Teer, J.,CO-PI:Mulé, J.
  • Developing a Novel Oncolytic Virus with Potent Cytotoxic and Immune Stimulatory Activity
    Sponsor: Moffitt Cancer Center
    PI (Contact):Beg, A.
  • THE CANCER EPITOPE DATABASE AND ANALYSIS RESOURCE
    Sponsor: Nat Institutes of Health
    PI:Conejo-Garcia, J.
  • A low cost topical immunotherapy formulation suitable for treating cervical cancer in low- and middle- income countries and low resource settings in the U.S.
    Sponsor: Nat Institutes of Health
    PI:Pilon-Thomas, S.
  • Dissecting the immunological mechanisms associated with prostate cancer progression in African-American men and exploring epigenetics-based immune modulation for therapy
    Sponsor: Nat Institutes of Health
    PI:Adeegbe, D.
  • NSG Mouse Models to Evaluate the Efficacy of TIL
    Sponsor: Iovance Biotherapeutics
    PI:Pilon-Thomas, S.
  • Role of Bcl11b in CD4+ T Cells and Innate Lymphoid Cells
    Sponsor: Nat Institutes of Health
    PI:Avram, D.
  • Tolerogenic Dual Microparticle System for Treatment of Multiple Sclerosis
    Sponsor: Nat Institutes of Health
    PI (MPI):Avram, D.
  • High throughput screening assays to identify chemical probes targeting Hectd3, an E3 ubiquitin ligase
    Sponsor: Nat Institutes of Health
    PI (MPI):Avram, D.
  • Validating and tailored targeting of identified immune signature in the tumors of African-American Prostate cancer patients
    Sponsor: Mike Slive Foundation
    PI:Adeegbe, D.
  • Actionable cell stress mechanisms governing αb and gd T cell responses against ovarian cancer
    Sponsor: Moffitt Cancer Center
    PI (Contact):Conejo-Garcia, J.,CO-PI:Rodriguez, P.,CO-PI:Tworoger, S.
  • Metabolic cooperation between macrophages and prostate cancer cells as a mechanism of resistance
    Sponsor: Moffitt Cancer Center
    PI:Ruffell, B.
  • Developing an Oncolytic Virus to induce de novo T cell priming: impact on TIL generation and therapeutic efficacy
    Sponsor: Moffitt Cancer Center
    PI:Beg, A.
  • Role of Butyrophilins in Regulating T-Cell Activity
    Sponsor: Moffitt Cancer Center
    PI:Conejo-Garcia, J.
  • Mechanisms of functional heterogeneity of tumor associated macrophages in glioblastoma
    Sponsor: Ivy (Ben & Catherine) Fdtn
    PI:Veglia, F.
  • Exploratory and IND-enabling Preclinical Studies to Assess Pharmacology and Safety of Anti-BCMA γδ2 CAR-T cells Using In vitro and In vivo Models for the Treatment of Multiple Myeloma
    Sponsor: Bluebird Bio Inc
    PI (Contact):Abate Daga, D.
  • Preclinical studies of MEM-288
    Sponsor: Memgen
    PI:Beg, A.
  • Study of Anti-Tumor Immunity and Tissue Resident Memory Cell Development by NKG2D and Ribosomal Protein S6 Signaling in T cells
    Sponsor: Nat Institutes of Health
    PI:Guevara, J.
  • Tech Transfer support and clinical protocol development for the use of TIL in patients with melanoma
    Sponsor: Turnstone Biologics
    PI:Pilon-Thomas, S.,CO-PI:Mulé, J.
Publications
  • Jaishankar D, Cosgrove C, Ramesh P, Mahon J, Shivde R, Dellacecca ER, Yang SF, Mosenson J, Guevara-Patiño JA, Le Poole IC. HSP70iQ435A to subdue autoimmunity and support anti-tumor responses. Cell Stress Chaperones. 2021 Sep. Pubmedid: 34542825.
  • Mandriani B, Pelle' E, Pezzicoli G, Strosberg J, Abate-Daga D, Guarini A, Cives M, Porta C. Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treat Rev. 2021 Sep.100:102288. Pubmedid: 34525422.
  • de la Iglesia JV, Slebos RJC, Martin-Gomez L, Wang X, Teer JK, Tan AC, Gerke TA, Aden-Buie G, van Veen T, Masannat J, Chaudhary R, Song F, Fournier M, Siegel EM, Schabath MB, Wadsworth JT, Caudell J, Harrison L, Wenig BM, Conejo-Garcia J, Hernandez-Prera JC, Chung CH. Correction: Effects of Tobacco Smoking On the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2021 Sep.27(17):4941. Pubmedid: 34470812.
  • Zhang Y, Seminario-Vidal L, Varnadoe C, Lu Y, Dong N, Salamanca C, Whiddon S, Bennett J, Hargis R, Liu H, Montejo M, Hussaini M, Harro C, Messina J, Benson K, Pinilla-Ibarz J, Conejo-Garcia J, Sokol L. Clinical characteristics and prognostic factors of 70 patients with Sézary syndrome: a single-institutional experience at Moffitt cancer center. Leuk Lymphoma. 2021 Sep.1-8. Pubmedid: 34467825.
  • Li R, Zhang J, Gilbert SM, Conejo-Garcia J, Mulé JJ. Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer. Nat Rev Urol. 2021 Sep.18(9):543-555. Pubmedid: 34183833.
  • Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. Nat Med. 2021 Aug.27(8):1410-1418. Pubmedid: 34385708.
  • Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021 Aug.21(8):485-498. Pubmedid: 33526920. Pmcid: PMC7849958.
  • Chakiryan NH, Kimmel GJ, Kim Y, Johnson JO, Clark N, Hajiran A, Chang A, Aydin AM, Zemp L, Katende E, Chahoud J, Ferrall-Fairbanks MC, Spiess PE, Francis N, Fournier M, Dhillon J, Park JY, Wang L, Mulé JJ, Altrock PM, Manley BJ. Geospatial Cellular Distribution of Cancer-Associated Fibroblasts Significantly Impacts Clinical Outcomes in Metastatic Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2021 Jul.13(15). Pubmedid: 34359645. Pmcid: PMC8345222.
  • El-Kenawi A, Dominguez-Viqueira W, Liu M, Awasthi S, Abraham-Miranda J, Keske A, Steiner KK, Noel L, Serna AN, Dhillon J, Gillies RJ, Yu X, Koomen JM, Yamoah K, Gatenby RA, Ruffell B. Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer. Cancer Res. 2021 Jul. Pubmedid: 34301759.
  • Kirtane K, Elmariah H, Chung CH, Abate-Daga D. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead. J Immunother Cancer. 2021 Jul.9(7). Pubmedid: 34301811. Pmcid: PMC8311333.
  • Rodriguez PC, Ruffell B. Cavity macrophages stop anti-tumor T cells. Cancer Cell. 2021 Jul.39(7):900-902. Pubmedid: 34256904.
  • Chen DT, Chan W, Thompson ZJ, Thapa R, Beg AA, Saltos AN, Chiappori AA, Gray JE, Haura EB, Rose TA, Creelan B. Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer. PLoS One. 2021 Jul.16(7):e0252041. Pubmedid: 34197475. Pmcid: PMC8248740.
  • Smalley I, Chen Z, Phadke MS, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases. Clin Cancer Res. 2021 Jul.27(14):4109-4125. Pubmedid: 34035069. Pmcid: PMC8282775.
  • Innamarato P, Morse J, Mackay A, Asby S, Beatty M, Blauvelt J, Kidd S, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors. BMC Cancer. 2021 Jun.21(1):756. Pubmedid: 34187428. Pmcid: PMC8243723.
  • Aoyama S, Nakagawa R, Nemoto S, Perez-Villarroel P, Mulé JJ, Mailloux AW. Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment. J Immunother Cancer. 2021 Jun.9(6). Pubmedid: 34135102. Pmcid: PMC8211075.
  • Li MO, Wolf N, Raulet DH, Akkari L, Pittet MJ, Rodriguez PC, Kaplan RN, Munitz A, Zhang Z, Cheng S, Bhardwaj N. Innate immune cells in the tumor microenvironment. Cancer Cell. 2021 Jun.39(6):725-729. Pubmedid: 34129817.
  • Van Vliet A, Girardot A, Bouchez J, Bigness A, Wang K, Moino D, Theodotou A, Pothuraju T, Felder S, Smith P, Kumar A, Dayicioglu D. How Big Is Too Big?: The Effect of Defect Size on Postoperative Complications of Vertical Rectus Abdominis Flap Reconstruction. Ann Plast Surg. 2021 Jun.86(6S Suppl 5):S571-S574. Pubmedid: 34100815.
  • de Mingo Pulido Á, Hänggi K, Celias DP, Gardner A, Li J, Batista-Bittencourt B, Mohamed E, Trillo-Tinoco J, Osunmakinde O, Peña R, Onimus A, Kaisho T, Kaufmann J, McEachern K, Soliman H, Luca VC, Rodriguez PC, Yu X, Ruffell B. The inhibitory receptor TIM-3 limits activation of the cGAS-STING pathway in intra-tumoral dendritic cells by suppressing extracellular DNA uptake. Immunity. 2021 Jun.54(6):1154-1167.e7. Pubmedid: 33979578. Pmcid: PMC8192496.
  • Chakiryan NH, Hajiran A, Kim Y, Aydin AM, Zemp L, Katende E, Nguyen J, Fan W, Cheng CH, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, Mulé J, Du D, Yoder SJ, Berglund A, Teer JK, Manley BJ. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma. Eur Urol Focus. 2021 May. Pubmedid: 33994165.
  • Phadke MS, Chen Z, Li J, Mohamed E, Davies MA, Smalley I, Duckett D, Palve V, Czerniecki BJ, Forsyth PA, Noyes D, Adeegbe DO, Eroglu Z, Nguyen KT, Tsai KY, Rix U, Burd CE, Chen YA, Rodriguez PC, Smalley KSM. Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity. Cancer Immunol Res. 2021 May.9(5):554-567. Pubmedid: 33653716. Pmcid: PMC8102376.
  • Mandula JK, Rodriguez PC. Tumor-related stress regulates functional plasticity of MDSCs. Cell Immunol. 2021 May.363:104312. Pubmedid: 33652258. Pmcid: PMC8026602.
  • Aydin AM, Hall M, Bunch BL, Branthoover H, Sannasardo Z, Mackay A, Beatty M, Sarnaik AA, Mullinax JE, Spiess PE, Pilon-Thomas S. Expansion of tumor-infiltrating lymphocytes (TIL) from penile cancer patients. Int Immunopharmacol. 2021 May.94:107481. Pubmedid: 33636562. Pmcid: PMC8205103.
  • Jain MD, Zhao H, Wang X, Atkins R, Menges M, Reid K, Spitler K, Faramand R, Bachmeier CA, Dean EA, Cao B, Chavez JC, Shah BD, Lazaryan A, Nishihori T, Hussaini MO, Gonzalez RJ, Mullinax JE, Rodriguez P, Conejo-Garcia J, Anasetti C, Davila ML, Locke FL. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. Blood. 2021 May.137(19):2621-2633. Pubmedid: 33512407. Pmcid: PMC8120145.
  • Xie M, Lee K, Lockhart JH, Cukras SD, Carvajal R, Beg AA, Flores ER, Teng M, Chung CH, Tan AC. TIMEx: tumor-immune microenvironment deconvolution web-portal for bulk transcriptomics using pan-cancer scRNA-seq signatures. Bioinformatics. 2021 Apr. Pubmedid: 33901274.
  • Chakiryan NH, Kimmel GJ, Kim Y, Hajiran A, Aydin AM, Zemp L, Katende E, Nguyen J, Lopez-Blanco N, Chahoud J, Spiess PE, Fournier M, Dhillon J, Wang L, Moran-Segura C, El-Kenawi A, Mulé J, Altrock PM, Manley BJ. Spatial clustering of CD68+ tumor associated macrophages with tumor cells is associated with worse overall survival in metastatic clear cell renal cell carcinoma. PLoS One. 2021 Apr.16(4):e0245415. Pubmedid: 33882057. Pmcid: PMC8059840.
  • Drashansky TT, Helm EY, Curkovic N, Cooper J, Cheng P, Chen X, Gautam N, Meng L, Kwiatkowski AJ, Collins WO, Keselowsky BG, Sant'Angelo D, Huo Z, Zhang W, Zhou L, Avram D. BCL11B is positioned upstream of PLZF and RORγt to control thymic development of mucosal-associated invariant T cells and MAIT17 program. iScience. 2021 Apr.24(4):102307. Pubmedid: 33870128. Pmcid: PMC8042176.
  • Reyes RM, Deng Y, Zhang D, Ji N, Mukherjee N, Wheeler K, Gupta HB, Padron AS, Kancharla A, Zhang C, Garcia M, Kornepati AVR, Boyman O, Conejo-Garcia JR, Svatek RS, Curiel TJ. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. J Immunother Cancer. 2021 Apr.9(4). Pubmedid: 33849925. Pmcid: PMC8051418.
  • Falahat R, Berglund A, Putney RM, Perez-Villarroel P, Aoyama S, Pilon-Thomas S, Barber GN, Mulé JJ. Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proc Natl Acad Sci U S A. 2021 Apr.118(15). Pubmedid: 33827917. Pmcid: PMC8053941.
  • Peres LC, Townsend MK, Birmann BM, Conejo-Garcia JR, Kim Y, Kubzansky LD, Magpantay LI, Martínez-Maza O, Tworoger SS. Circulating Biomarkers of Inflammation and Ovarian Cancer Risk in the Nurses' Health Studies. Cancer Epidemiol Biomarkers Prev. 2021 Apr.30(4):710-718. Pubmedid: 33563649.
  • Veglia F, Hashimoto A, Dweep H, Sanseviero E, De Leo A, Tcyganov E, Kossenkov A, Mulligan C, Nam B, Masters G, Patel J, Bhargava V, Wilkinson P, Smirnov D, Sepulveda MA, Singhal S, Eruslanov EB, Cristescu R, Loboda A, Nefedova Y, Gabrilovich DI. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021 Apr.218(4). Pubmedid: 33566112. Pmcid: PMC7879582.
  • Jia Y, Kodumudi KN, Ramamoorthi G, Basu A, Snyder C, Wiener D, Pilon-Thomas S, Grover P, Zhang H, Greene MI, Mo Q, Tong Z, Chen YZ, Costa RLB, Han H, Lee C, Soliman H, Conejo-Garcia JR, Koski G, Czerniecki BJ. Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway. Mol Ther. 2021 Apr.29(4):1541-1556. Pubmedid: 33412308. Pmcid: PMC8058490.
  • Hajiran A, Chakiryan N, Aydin AM, Zemp L, Nguyen J, Laborde JM, Chahoud J, Spiess PE, Zaman S, Falasiri S, Fournier M, Teer JK, Dhillon J, McCarthy S, Moran-Segura C, Katende EN, Sexton WJ, Koomen JM, Mulé J, Kim Y, Manley B. Reconnaissance of tumor immune microenvironment spatial heterogeneity in metastatic renal cell carcinoma and correlation with immunotherapy response. Clin Exp Immunol. 2021 Apr.204(1):96-106. Pubmedid: 33346915. Pmcid: PMC7944355.
  • Zaman S, Hajiran A, Coba GA, Robinson T, Madanayake TW, Segarra DT, Chobrutskiy BI, Boyle TA, Zhou JM, Kim Y, Mulé JJ, Teer JK, Manley BJ. Aberrant Epidermal Growth Factor Receptor RNA Splice Products Are Among the Most Frequent Somatic Alterations in Clear Cell Renal Cell Carcinoma and Are Associated with a Poor Response to Immunotherapy. Eur Urol Focus. 2021 Mar.7(2):373-380. Pubmedid: 31901438. Pmcid: PMC7771328.
  • Alicea-Torres K, Sanseviero E, Gui J, Chen J, Veglia F, Yu Q, Donthireddy L, Kossenkov A, Lin C, Fu S, Mulligan C, Nam B, Masters G, Denstman F, Bennett J, Hockstein N, Rynda-Apple A, Nefedova Y, Fuchs SY, Gabrilovich DI. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nat Commun. 2021 Mar.12(1):1717. Pubmedid: 33741967. Pmcid: PMC7979850.
  • Holmes TD, Pandey RV, Helm EY, Schlums H, Han H, Campbell TM, Drashansky TT, Chiang S, Wu CY, Tao C, Shoukier M, Tolosa E, Von Hardenberg S, Sun M, Klemann C, Marsh RA, Lau CM, Lin Y, Sun JC, Månsson R, Cichocki F, Avram D, Bryceson YT. The transcription factor Bcl11b promotes both canonical and adaptive NK cell differentiation. Sci Immunol. 2021 Mar.6(57). Pubmedid: 33712472. Pmcid: PMC8274449.
  • Valisno JAC, May J, Singh K, Helm EY, Venegas L, Budbazar E, Goodman JB, Nicholson CJ, Avram D, Cohen RA, Mitchell GF, Morgan KG, Seta F. BCL11B Regulates Arterial Stiffness and Related Target Organ Damage. Circ Res. 2021 Mar.128(6):755-768. Pubmedid: 33530702. Pmcid: PMC7969164.
  • Biswas S, Mandal G, Payne KK, Anadon CM, Gatenbee CD, Chaurio RA, Costich TL, Moran C, Harro CM, Rigolizzo KE, Mine JA, Trillo-Tinoco J, Sasamoto N, Terry KL, Marchion D, Buras A, Wenham RM, Yu X, Townsend MK, Tworoger SS, Rodriguez PC, Anderson AR, Conejo-Garcia JR. IgA transcytosis and antigen recognition govern ovarian cancer immunity. Nature. 2021 Mar.591(7850):464-470. Pubmedid: 33536615. Pmcid: PMC7969354.
  • Innamarato P, Pilon-Thomas S. Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy. Cell Immunol. 2021 Mar.361:104277. Pubmedid: 33476931. Pmcid: PMC7901256.
  • Aydin AM, Bunch BL, Beatty M, Hajiran A, Dhillon J, Sarnaik AA, Pilon-Thomas S, Poch MA. The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications. Front Immunol. 2021 Feb.12:628063. Pubmedid: 33717150. Pmcid: PMC7949015.
  • Kolb R, De U, Khan S, Luo Y, Kim MC, Yu H, Wu C, Mo J, Zhang X, Zhang P, Zhang X, Borcherding N, Koppel D, Fu YX, Zheng SG, Avram D, Zheng G, Zhou D, Zhang W. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021 Feb.12(1):1281. Pubmedid: 33627663. Pmcid: PMC7904819.
  • Mullinax JE, Hall M, Beatty M, Weber AM, Sannasardo Z, Svrdlin T, Hensel J, Richards A, Gonzalez RJ, Cox CA, Kelley L, Mulé JJ, Sarnaik AA, Pilon-Thomas S. Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function. J Immunother. 2021 Feb.44(2):63-70. Pubmedid: 33443972. Pmcid: PMC8111686.
  • Chaudhary R, Slebos RJC, Song F, McCleary-Sharpe KP, Masannat J, Tan AC, Wang X, Amaladas N, Wu W, Hall GE, Conejo-Garcia JR, Hernandez-Prera JC, Chung CH. Effects of checkpoint kinase 1 inhibition by prexasertib on the tumor immune microenvironment of head and neck squamous cell carcinoma. Mol Carcinogen. 2021 Feb.60(2):138-150. Pubmedid: 33378592. Pmcid: PMC7856233.
  • Harro CM, Perez-Sanz J, Costich TL, Payne KK, Anadon Galindo CM, Chaurio RA, Biswas S, Mandal G, Rigolizzo KE, Sprenger KB, Mine JA, Showe L, Yu X, Liu K, Rodriguez PC, Pinilla-Ibarz J, Sokol L, Conejo-Garcia JR. Methyltransferase inhibitors restore SATB1 protective activity against cutaneous T cell lymphoma in mice. J Clin Invest. 2021 Feb.131(3). Pubmedid: 33270606. Pmcid: PMC7843215.
  • Perez BA, Kim S, Wang M, Karimi AM, Powell C, Li J, Dilling TJ, Chiappori A, Latifi K, Rose T, Lannon A, MacMillan G, Saller J, Grass GD, Rosenberg S, Gray J, Haura E, Creelan B, Tanvetyanon T, Saltos A, Shafique M, Boyle TA, Schell MJ, Conejo-Garcia JR, Antonia SJ. Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2021 Feb.109(2):425-435. Pubmedid: 33002543.
  • Koşaloğlu-Yalçın Z, Blazeska N, Carter H, Nielsen M, Cohen E, Kufe D, Conejo-Garcia J, Robbins P, Schoenberger SP, Peters B, Sette A. The Cancer Epitope Database and Analysis Resource: A Blueprint for the Establishment of a New Bioinformatics Resource for Use by the Cancer Immunology Community. Front Immunol. 2021 Aug.12:735609. Pubmedid: 34504503. Pmcid: PMC8421848.
  • Li R, Berglund A, Zemp L, Dhillon J, Putney R, Kim Y, Jain RK, Grass GD, Conejo-Garcia J, Mulé JJ. The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Front Immunol. 2021 Jun.12:694079. Pubmedid: 34267760. Pmcid: PMC8276102.
  • Aoyama S, Nakagawa R, Mulé JJ, Mailloux AW. Inducible Tertiary Lymphoid Structures: Promise and Challenges for Translating a New Class of Immunotherapy. Front Immunol. 2021 May.12:675538. Pubmedid: 34054863. Pmcid: PMC8160316.
  • Wilson CM, Fridley BL, Conejo-Garcia JR, Wang X, Yu X. Wide and deep learning for automatic cell type identification. Comput Struct Biotechnol J. 2021 Jan.19:1052-1062. Pubmedid: 33613870. Pmcid: PMC7878986.
  • Trizzino M, Zucco A, Deliard S, Wang F, Barbieri E, Veglia F, Gabrilovich D, Gardini A. EGR1 is a gatekeeper of inflammatory enhancers in human macrophages. Sci Adv. 2021 Jan.7(3). Pubmedid: 33523892. Pmcid: PMC7806227.
  • Dalton R, Calescibetta A, Zhou JM, Maurin M, Ward G, Trinh TL, Tu N, Gilvary D, Chen X, Cheng P, Kostenko E, Wei S, Wright KL, Eksioglu EA. Constitutively Activated DAP12 Induces Functional Anti-Tumor Activation and Maturation of Human Monocyte-Derived DC. Int J Mol Sci. 2021 Jan.22(3). Pubmedid: 33513928. Pmcid: PMC7865632.
  • Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, Lopez J, Nandre R, Zeng P, Alolaqi F, Ahmad S, Gaur P, Barry ST, Valge-Archer VE, Smith PD, Banchereau J, Mkrtichyan M, Youngblood B, Rodriguez PC, Gupta S, Khleif SN. MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. Nat Immunol. 2021 Jan.22(1):53-66. Pubmedid: 33230330.
  • Watters JM, Wright G, Smith MA, Shah B, Wright KL. Histone deacetylase 8 inhibition suppresses mantle cell lymphoma viability while preserving natural killer cell function. Biochem Bioph Res Co. 2021 Jan.534:773-779. Pubmedid: 33190829. Pmcid: PMC7785659.
  • Ketcher DE, Bidelman A, Le LQ, Otto AK, Lester DK, Amtmann-Beuttner KK, Gonzalez B, Wright KL, Vadaparampil ST, Reblin M, Lau EK. Partnering patients, caregivers, and basic scientists: an engagement model that fosters patient- and family-centered research culture. Transl Res. 2021 Jan.227:64-74. Pubmedid: 32739418. Pmcid: PMC7719089.
  • De Leo A, Ugolini A, Veglia F. Myeloid Cells in Glioblastoma Microenvironment. Cells. 2020 Dec.10(1). Pubmedid: 33374253. Pmcid: PMC7824606.
  • Mo Q, Li R, Adeegbe DO, Peng G, Chan KS. Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy. Commun Biol. 2020 Dec.3(1):784. Pubmedid: 33335285. Pmcid: PMC7746703.
  • Bunch BL, Morse J, Asby S, Blauvelt J, Aydin AM, Innamarato P, Hajiran A, Beatty M, Poch M, Pilon-Thomas S. Systemic and intravesical adoptive cell therapy of tumor-reactive T cells can decrease bladder tumor growth in vivo. J Immunother Cancer. 2020 Dec.8(2). Pubmedid: 33303579. Pmcid: PMC7733200.
  • Sharma V, Wright KL, Epling-Burnette PK, Reuther GW. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms. Front Immunol. 2020 Nov.11:604142. Pubmedid: 33329600. Pmcid: PMC7734315.
  • Garg SK, Welsh EA, Fang B, Hernandez YI, Rose T, Gray J, Koomen JM, Berglund A, Mulé JJ, Markowitz J. Multi-Omics and Informatics Analysis of FFPE Tissues Derived from Melanoma Patients with Long/Short Responses to Anti-PD1 Therapy Reveals Pathways of Response. Cancers (Basel). 2020 Nov.12(12). Pubmedid: 33255891. Pmcid: PMC7768436.
  • Innamarato P, Asby S, Morse J, Mackay A, Hall M, Kidd S, Nagle L, Sarnaik AA, Pilon-Thomas S. Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells. J Immunol. 2020 Nov.205(10):2893-2904. Pubmedid: 33020146. Pmcid: PMC7741883.
  • Drerup JM, Deng Y, Pandeswara SL, Padrón ÁS, Reyes RM, Zhang X, Mendez J, Liu A, Clark CA, Chen W, Conejo-Garcia JR, Hurez V, Gupta H, Curiel TJ. CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade. Cancer Res. 2020 Nov.80(22):5063-5075. Pubmedid: 32948605. Pmcid: PMC7669742.
  • Schipper J, Westerhuis JJ, Beddows I, Madaj Z, Monsma D, Hostetter G, Kiupel M, Conejo-Garcia JR, Sempere LF. Loss of microRNA-21 leads to profound stromal remodeling and short survival in K-Ras-driven mouse models of pancreatic cancer. Int J Cancer. 2020 Oct.147(8):2265-2278. Pubmedid: 32388866.
  • Innamarato P, Kodumudi K, Asby S, Schachner B, Hall M, Mackay A, Wiener D, Beatty M, Nagle L, Creelan BC, Sarnaik AA, Pilon-Thomas S. Reactive Myelopoiesis Triggered by Lymphodepleting Chemotherapy Limits the Efficacy of Adoptive T Cell Therapy. Mol Ther. 2020 Oct.28(10):2252-2270. Pubmedid: 32615068. Pmcid: PMC7544980.
  • Wang W, Marinis JM, Beal AM, Savadkar S, Wu Y, Khan M, Taunk PS, Wu N, Su W, Wu J, Ahsan A, Kurz E, Chen T, Yaboh I, Li F, Gutierrez J, Diskin B, Hundeyin M, Reilly M, Lich JD, Harris PA, Mahajan MK, Thorpe JH, Nassau P, Mosley JE, Leinwand J, Kochen Rossi JA, Mishra A, Aykut B, Glacken M, Ochi A, Verma N, Kim JI, Vasudevaraja V, Adeegbe D, Almonte C, Bagdatlioglu E, Cohen DJ, Wong KK, Bertin J, Miller G. RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. Cancer Cell. 2020 Oct.38(4):585-590. Pubmedid: 33049209.